Cancer Drug News Protected: Tecartus® (Brexucabtagene Autoleucel) CAR T-cell therapy now funded in Australia for the treatment of relapsed or refractory mantle cell lymphoma (r/r MCL)
Fast-tracked cancer drug candidate causes substantial levels of mutations and must be investigated for risk of secondary cancer
Cancer Drug News Nivolumab subcutaneous formulation given approval across multiple solid tumour types in the UK May 10, 2025 Bristol Myers Squibb (BMS) has announced that the UK Medicines and Healthcare products Regulatory Agency…
Cancer Drug News New study highlights success of Financial Toxicity Tumour Board in reducing cancer treatment costs May 7, 2025 Financial toxicity, the financial distress linked to cancer treatment, significantly impacts patient outcomes. To combat…
Cancer Drug News FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma May 4, 2025 On April 23, 2025, the Food and Drug Administration approved penpulimab-kcqx with cisplatin or carboplatin…
Cancer Drug News NICE approves dual immunotherapy for the first line treatment of adult patients with mismatch repair deficient or microsatellite instability high unresectable or metastatic colorectal cancer approved in the UK May 4, 2025 Nivolumab in combination with ipilimumab has been granted an indication extension in the UK by…
Cancer Drug News Enfortumab vedotin plus pembrolizumab in advanced bladder cancer: Hint of major added benefit April 18, 2025 Urothelium is the term for the mucous membrane that lines the urinary tract. This includes…
Cancer Drug News How oncologists respond to negative trials April 5, 2025 FDA Withdrawals and Oncology Drug Use The U.S. Food and Drug Administration’s (FDA) accelerated approval…
Cancer Drug News FDA approves cabozantinib for adults and paediatric patients 12 years of age and older with pNET and epNET April 5, 2025 On March 26, 2025, the Food and Drug Administration approved cabozantinib (Cabometyx, Exelixis, Inc.) for…
Cancer Drug News FDA approves dual-action drug for patients with previously treated advanced neuroendocrine tumours April 2, 2025 Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug…
Cancer Drug News FDA approves pembrolizumab for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1) March 31, 2025 On March 19, 2025, the Food and Drug Administration granted traditional approval to pembrolizumab with…
Cancer Drug News FDA approves vimseltinib for symptomatic tenosynovial giant cell tumour March 14, 2025 On February 14, 2025, the Food and Drug Administration approved vimseltinib, a kinase inhibitor, for…